Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress
August 10, 2020 07:30 ET
|
Revolution Medicines, Inc.
Interim RMC-4630 Data Support Benefit of Intermittent Dosing and Corroborate Clinical Activity Against Genetically-Defined Tumors Targeted Combination Strategy Underpins Initiation of New Clinical...
Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock
July 08, 2020 22:48 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock...
Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress
May 14, 2020 16:05 ET
|
Revolution Medicines, Inc.
Closed Initial Public Offering Raising Gross Proceeds of $273.7 Million Presented First Evidence of Clinical Activity of SHP2 Inhibitor (RMC-4630) Against KRAS Mutant Lung Cancers Preclinical...
Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
April 29, 2020 08:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...